New clinical data on lecanemab to be presented at CTAD conference 2026

STOCKHOLM, October 30, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi®) at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, November 16-19, 2026. The...

Read the full story at BioArctic via PR Newswire (opens in a new tab)

Headline and summary from BioArctic via PR Newswire; the full story is on the publisher's site. Nothing here is investment advice.